Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lung Neoplasms × Radiotherapy, Intensity-Modulated × Clear all

Phase

Status

Sponsor Class

OTHER 11 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 5 Stomatitis 3 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Mucositis 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Glioblastoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Camurati-Engelmann Syndrome 1

Interventions

Carboplatin 97 Pemetrexed 70 pembrolizumab 68 Cisplatin 59 Paclitaxel 54 Docetaxel 45 Gemcitabine 37 Erlotinib Hydrochloride 24 Nivolumab 23 osimertinib 17 Bevacizumab 17 durvalumab 14 Cetuximab 13 130-nm albumin-bound paclitaxel 13 Gefitinib 11 Drug Therapy 11 Etoposide 10 Ipilimumab 9 Injections 9 Albumin-Bound Paclitaxel 9 Vinorelbine 8 Radiotherapy 8 motexafin gadolinium 7 capmatinib 7 epacadostat 6 atezolizumab 6 Taxes 6 Cyclophosphamide 6 vandetanib 5 entinostat 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01266512 2014-07-16

C-CRISP

Sanofi

Phase 2 Completed

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡